ArticleCancer science2022
The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.
Article in Cancer science, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 29 citations in OpenAlex.
- Antitumor Activity of Cannabinoids and Their Interaction with Chemotherapy: A Systematic Review and Meta-Analysis of Preclinical Evidence.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.Federal practitioner : for the health care professionals of the VA, DoD, and PHS · 2026Article
- Review
- Mechanistic study of the cytotoxicity of cannabidiol and its metabolites in HepG2 cells.Archives of toxicology · 2026Article
- Bioinformatics differential expression analysis of the effect of cannabidiol in chronic myeloid leukaemia cell line.Global medical genetics · 2025Article
- Dual-Gating Strategy: Ultrasound Activation of TRPV2 Channels and Borate-Glass-Induced Calcium Overload for Tumor Suppression.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Cannabidiol suppresses proliferation and induces cell death, autophagy and senescence in human cholangiocarcinoma cells via the PI3K/AKT/mTOR pathway.Journal of traditional and complementary medicine · 2024Article
- Leukemia and mitophagy: a novel perspective for understanding oncogenesis and resistance.Annals of hematology · 2024Review
- Review
- Research Progress on the Mechanism of the Antitumor Effects of Cannabidiol.Molecules (Basel, Switzerland) · 2024Review
- TRP channels associated with macrophages as targets for the treatment of obese asthma.Lipids in health and disease · 2024Review
- Mitochondrial abnormalities as a target of intervention in acute myeloid leukemia.Frontiers in oncology · 2024Review
- Targeting Nrf2 Signaling Pathway in Cancer Prevention and Treatment: The Role of Cannabis Compounds.Antioxidants (Basel, Switzerland) · 2023Review
- Cannabidiol Inhibits the Proliferation and Invasiveness of Prostate Cancer Cells.Journal of natural products · 2023Article
- Correction.Cancer science · 2023Article
- Calcium influx, oxidative stress, and apoptosis induced by TRPV1 in chronic myeloid leukemia cells: Synergistic effects with imatinib.Frontiers in molecular biosciences · 2023Article
- Mitophagy: A novel perspective for insighting into cancer and cancer treatment.Cell proliferation · 2022Review
- Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective.Signal transduction and targeted therapy · 2022Review
- The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.Cancer science · 2022Article
- Deregulated calcium signaling in blood cancer: Underlying mechanisms and therapeutic potential.Frontiers in oncology · 2022Review
Corrections and comments
- Erratum issuedCorrection.2023
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by accumulation of immature cells in bone marrow and peripheral blood. Although successful results were obtained with tyrosine kinase inhibitors, several patients showed resistance. For this reason, the identification of new strategies and therapeutic biomarkers represents an attractive goal. The role of transient receptor potential (TRP) ion channels as possible drug targets has been elucidated in different types of cancer. Among natural compounds known to activate TRPs, cannabidiol (CBD) displays anticancer properties. By using FACS analysis, confocal microscopy, gene silencing, and cell growth assay, we demonstrated that CBD, through TRPV2, inhibits cell proliferation and cell cycle in CML cells. It promoted mitochondria dysfunction and mitophagy as shown by mitochondrial mass reduction and up-regulation of several mitophagy markers. These effects were associated with changes in the expression of octamer-binding transcription factor 4 and PU.1 markers regulated during cellular differentiation. Interestingly, a synergistic effect by combining CBD with the standard drug imatinib was found and imatinib-resistant cells remain susceptible to CBD effects. Therefore, the targeting of TRPV2 by using CBD, through the activation of mitophagy and the reduction in stemness, could be a promising strategy to enhance conventional therapy and improve the prognosis of CML patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.